Related Experiment Video
Updated: May 16, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)
Jung Hwa Lee1, Sang Tae Choi, Jin Su Kim
1Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, 4-12 Hwayang-dong Gwangjin-gu, Seoul 143-729, Korea.
Abstract:
Polymyalgia rheumatica (PMR) is a common inflammatory disease of the elderly in western countries, but the prevalence is apparently different between races and countries. Until now, an epidemiologic study of PMR is limited in Korea. We retrospectively evaluated the clinical data of 78 patients with PMR who were treated in 5 tertiary hospitals, and analyzed initial laboratory data, symptoms, therapeutic responses, and prognostic factors for relapse 1 year after treatments. Sixty percent of patients had pain in both shoulder and hip girdles with 10.6 weeks of duration, 75.9 ± 32.7 mm/h of erythrocyte sedimentation rate (ESR), and 6.2 ± 6.4 mg/dl of C-reactive protein. The rate of relapse and remission at 1 year was 38.4 and 2.5 %, respectively. The rate of overall relapse was 46.1 %, and the relapse occurred mostly in a year, especially between 6 and 12 months after diagnosis. There were more female in relapse group (88.9 %, p = 0.037), and cumulative steroid dose of 1 year was significantly higher in relapse group (5.5 ± 2.7 vs. 4.4 ± 2.5 g, p = 0.018). Independent risk factors for relapse were initial CRP ≥ 2.5 mg/dl (OR 6.296, p = 0.047) and the use of hydroxychloroquine (OR 6.798, p = 0.035). Initial dosage or tapering speed of steroid did not influence on prognosis. In Korean patients with PMR, baseline clinical characteristics and relapse rate were similar to previous studies, but our patients accompanied no giant cell arteritis and showed lower remission rate as well as delayed therapeutic response and later occurrence of relapse. More aggressive management would be needed according to the clinical status of patients.
Insights
Polymyalgia rheumatica (PMR) in Korean patients shows similar characteristics to Western populations but with a lower remission rate. Relapse risk factors include high initial C-reactive protein and hydroxychloroquine use, suggesting a need for tailored management strategies.
Area of Science:
- Rheumatology
- Epidemiology
- Internal Medicine
Background:
- Polymyalgia rheumatica (PMR) is a common inflammatory condition in the elderly, with varying prevalence across different populations.
- Epidemiological data on PMR in Korea is limited, necessitating further investigation into its characteristics within this demographic.
Purpose of the Study:
- To retrospectively evaluate the clinical data of Korean patients diagnosed with PMR.
- To analyze initial laboratory findings, symptoms, treatment responses, and prognostic factors for relapse within one year.
Main Methods:
- Retrospective analysis of clinical data from 78 PMR patients treated at five tertiary hospitals.
- Evaluation of initial laboratory data, symptoms, therapeutic responses, and relapse rates at one year.
Main Results:
- Sixty percent of patients experienced shoulder and hip girdle pain, with elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
- The 1-year relapse rate was 38.4%, with overall relapse at 46.1%, occurring predominantly within the first year.
- Independent risk factors for relapse included initial CRP ≥ 2.5 mg/dl and hydroxychloroquine use; female gender and higher cumulative steroid dose were associated with relapse.
Conclusions:
- Korean PMR patients exhibit similar baseline characteristics and relapse rates to Western cohorts but notably lack associated giant cell arteritis.
- Lower remission rates, delayed therapeutic response, and later relapse occurrence were observed in this Korean cohort.
- More aggressive and individualized management strategies may be required for Korean patients with PMR based on their clinical status and identified risk factors.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Pericarditis II: Clinical Features and Diagnostic Tests
Multiple Sclerosis l: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy IV: Restrictive Cardiomyopathy